Skip to Main Content
Table 1

Baseline characteristics of the patients

Control groupContinuous monitoring group
N 58 62 
Female sex, number (%) 19 (33) 26 (42) 
Age (years)* 26.0 ± 14.6 25.7 ± 14.1 
Pediatric, number (%) 26 (45) 27 (44) 
BMI (kg/m2)* 22.0 ± 3.8 22.4 ± 3.8 
Duration of diabetes (years)* 11.4 ± 11.4 11.6 ± 11.3 
Insulin administration, number (%)   
 Pump 34 (59) 47 (76) 
 MDI 24 (41) 15 (24) 
Glycated hemoglobin at screening (%)* 6.90 ± 0.47 6.83 ± 0.44 
Glycated hemoglobin at baseline (%)* 6.91 ± 0.67 6.92 ± 0.56 
Record of severe hypoglycemia in last year, number (%) 7 (12) 5 (8) 
Diagnosed with hypoglycemia unawareness, number (%) 4 (7) 6 (10) 
Daily insulin dose (units/kg)* 0.67 ± 0.32 0.66 ± 0.25 
Education, number (%)   
 Pediatric patient still in education 26 (45) 29 (47) 
 Completed education by age 18 3 (5) 6 (10) 
 Completed further education 29 (50) 27 (44) 
Prior use of continuous glucose monitor, number (%) 18 (31) 21 (34) 
Mean blood glucose in 1-month run-in period (mg/dL)* 148 ± 28 147 ± 23 
SMBG measurements per day in 1-month run-in period* 5.1 ± 2.5 5.3 ± 2.2 
Control groupContinuous monitoring group
N 58 62 
Female sex, number (%) 19 (33) 26 (42) 
Age (years)* 26.0 ± 14.6 25.7 ± 14.1 
Pediatric, number (%) 26 (45) 27 (44) 
BMI (kg/m2)* 22.0 ± 3.8 22.4 ± 3.8 
Duration of diabetes (years)* 11.4 ± 11.4 11.6 ± 11.3 
Insulin administration, number (%)   
 Pump 34 (59) 47 (76) 
 MDI 24 (41) 15 (24) 
Glycated hemoglobin at screening (%)* 6.90 ± 0.47 6.83 ± 0.44 
Glycated hemoglobin at baseline (%)* 6.91 ± 0.67 6.92 ± 0.56 
Record of severe hypoglycemia in last year, number (%) 7 (12) 5 (8) 
Diagnosed with hypoglycemia unawareness, number (%) 4 (7) 6 (10) 
Daily insulin dose (units/kg)* 0.67 ± 0.32 0.66 ± 0.25 
Education, number (%)   
 Pediatric patient still in education 26 (45) 29 (47) 
 Completed education by age 18 3 (5) 6 (10) 
 Completed further education 29 (50) 27 (44) 
Prior use of continuous glucose monitor, number (%) 18 (31) 21 (34) 
Mean blood glucose in 1-month run-in period (mg/dL)* 148 ± 28 147 ± 23 
SMBG measurements per day in 1-month run-in period* 5.1 ± 2.5 5.3 ± 2.2 

Differences between the control and the continuous monitoring group were not statistically significant. MDI, multiple daily injection.

*Means ± SD.

Close Modal

or Create an Account

Close Modal
Close Modal